Skip to main content
. 2024 Oct 5;17:3267–3275. doi: 10.2147/JPR.S471160

Table 2.

Outcomes for Patients on Buprenorphine, Methadone and Naltrexone for Chronic Pain 

POE Visit (N=193) No POE Visit (N=379) Unweighted Weighted
Estimate* 95% CI p-value Estimate* 95% CI p-value
Total perioperative opioids, median (IQR)ª 76.1 (15.1, 156.6) 56.0 (0.1, 150.1) 1.45 (1.02, 2.08) 0.041 1.43 (0.95, 2.16) 0.087
Hospital length of stay, median (IQR)ª 2.4 (1.3, 4.4) 2.3 (1.0, 5.3) 1.02 (0.86, 1.22) 0.816 1.01 (0.81, 1.25) 0.939
Perioperative multimodal analgesics, n (%) 179 (93%) 331 (87%) 1.86 (1.01, 3.43) 0.046 2.33 (1.17, 4.65) 0.016
Perioperative complications, n (%) 18 (9%) 53 (14%) 0.63 (0.36, 1.10) 0.105 0.71 (0.39, 1.29) 0.261
Inpatient pain service, n (%) 61 (32%) 118 (31%) 1.03 (0.73, 1.46) 0.870 1.13 (0.74, 1.71) 0.568
Readmitted within 30 days, n (%) 41 (21%) 84 (22%) 0.93 (0.62, 1.42) 0.751 1.19 (0.75, 1.88) 0.462
Procedure cancelled, n (%) 0 (0%) 0 (0%)
Post-surgical addiction medicine consult, n (%) 0 (0%) 0 (0%)

Notes: The reference group is no POE visit. Estimates are the multiplicative change in the outcome for total perioperative opioid consumption, hospital length of stay, and total multimodal perioperative analgesics. Estimates are Odds Ratios for perioperative complications, inpatient pain service, readmitted within 30 days, and withdrawal or relapse.  ªData were log-transformed for normality.